Mechanisms of Disease: hepatic steatosis in type 2 diabetes—pathogenesis and clinical relevance
暂无分享,去创建一个
[1] G. Marchesini,et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. , 2001, Diabetes.
[2] Michael Roden,et al. Hepatic glucose metabolism in humans--its role in health and disease. , 2003, Best practice & research. Clinical endocrinology & metabolism.
[3] D. Doddrell,et al. Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected]. , 2002, Obesity research.
[4] A. Garg,et al. Effect of leptin replacement on intrahepatic and intramyocellular lipid content in patients with generalized lipodystrophy. , 2003, Diabetes care.
[5] L. J. Hardies,et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. , 2004, The Journal of clinical endocrinology and metabolism.
[6] Ekrem Orbay,et al. Association of Nonalcoholic Fatty Liver Disease With Insulin Resistance: Is OGTT Indicated in Nonalcoholic Fatty Liver Disease? , 2003, Journal of clinical gastroenterology.
[7] D. Joy,et al. Diagnosis of fatty liver disease: is biopsy necessary? , 2003, European journal of gastroenterology & hepatology.
[8] M. Roden,et al. Relative hypoleptinemia in patients with type 1 and type 2 diabetes mellitus , 2000, International Journal of Obesity.
[9] C. Cobelli,et al. Alterations in postprandial hepatic glycogen metabolism in type 2 diabetes. , 2004, Diabetes.
[10] G. Marchesini,et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. , 2005, The Journal of clinical endocrinology and metabolism.
[11] K. Petersen,et al. Nuclear magnetic resonance studies of hepatic glucose metabolism in humans. , 2001, Recent progress in hormone research.
[12] Peter Nowotny,et al. Increased lipid availability impairs insulin-stimulated ATP synthesis in human skeletal muscle. , 2006, Diabetes.
[13] D. Befroy,et al. Mechanism of Hepatic Insulin Resistance in Non-alcoholic Fatty Liver Disease* , 2004, Journal of Biological Chemistry.
[14] M. Roden,et al. Free fatty acids inhibit the glucose-stimulated increase of intramuscular glucose-6-phosphate concentration in humans. , 2001, The Journal of clinical endocrinology and metabolism.
[15] G. Farr,et al. Metformin in the treatment of non‐alcoholic steatohepatitis: a pilot open label trial , 2004, Alimentary pharmacology & therapeutics.
[16] G. Shulman,et al. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. , 2000, The Journal of clinical investigation.
[17] Emilio Ros,et al. Nonalcoholic Fatty Liver Disease Is Associated With Carotid Atherosclerosis: A Case–Control Study , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[18] A. Häkkinen,et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. , 2002, The Journal of clinical endocrinology and metabolism.
[19] R. DeFronzo,et al. Pathogenesis of type 2 diabetes mellitus. , 2004, The Medical clinics of North America.
[20] G. Marchesini,et al. Association of nonalcoholic fatty liver disease with insulin resistance. , 1999, The American journal of medicine.
[21] Vincent Lebon,et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. , 2002, Diabetes.
[22] M. Roden,et al. Effects of insulin treatment in type 2 diabetic patients on intracellular lipid content in liver and skeletal muscle. , 2002, Diabetes.
[23] A. Häkkinen,et al. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. , 2004, Diabetes.
[24] Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis , 2003, Hepatology.
[25] J. Kench,et al. Beyond insulin resistance in NASH: TNF‐α or adiponectin? , 2004, Hepatology.
[26] G. Targher,et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. , 2005, Diabetes.
[27] S. Sanderson,et al. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. , 2005, Journal of hepatology.
[28] Y. Tamura,et al. Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients. , 2005, The Journal of clinical endocrinology and metabolism.
[29] L. J. Hardies,et al. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. , 2003, Diabetes.
[30] I. Shimomura,et al. Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease. , 2005, The Journal of clinical investigation.
[31] K. Batts,et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis , 1999, Hepatology.
[32] A. Häkkinen,et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. , 2000, Diabetes.
[33] Jonathan C. Cohen,et al. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity , 2004, Hepatology.
[34] S. Shoelson,et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB , 2005, Nature Medicine.
[35] P. Macfarlane,et al. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. , 2004, Diabetes.
[36] K. Wellen,et al. Inflammation, stress, and diabetes. , 2005, The Journal of clinical investigation.
[37] B. Lowell,et al. Mitochondrial Dysfunction and Type 2 Diabetes , 2005, Science.
[38] A. Häkkinen,et al. Effects of identical weight loss on body composition and features of insulin resistance in obese women with high and low liver fat content. , 2003, Diabetes.
[39] M. Roden,et al. Hepatic leptin signaling in obesity , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[40] S. Sanderson,et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. , 2005, Gastroenterology.
[41] L. Adams,et al. Recent concepts in non‐alcoholic fatty liver disease , 2005, Diabetic medicine : a journal of the British Diabetic Association.
[42] C. Bogardus,et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. , 2002, Diabetes.
[43] G. Boden. Pathogenesis of type 2 diabetes. Insulin resistance. , 2001 .
[44] Donald D Hensrud,et al. Splanchnic lipolysis in human obesity. , 2004, The Journal of clinical investigation.
[45] R. Unger. Lipid overload and overflow: metabolic trauma and the metabolic syndrome , 2003, Trends in Endocrinology & Metabolism.
[46] A. Häkkinen,et al. Dietary fat content modifies liver fat in overweight nondiabetic subjects. , 2005, The Journal of clinical endocrinology and metabolism.
[47] Y. Takei,et al. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. , 2002, Gastroenterology.
[48] N. Tajima,et al. Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy--a randomized controlled trial. , 2001, Metabolism: clinical and experimental.
[49] G. Müller. The Molecular Mechanism of the Insulin-mimetic/sensitizing Activity of the Antidiabetic Sulfonylurea Drug Amaryl , 2000, Molecular medicine.
[50] Shyi-Jang Shin,et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. , 2006, The Journal of clinical endocrinology and metabolism.
[51] K. Petersen,et al. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. , 2005, Diabetes.
[52] I. G. Fantus,et al. Free fatty acid-induced hepatic insulin resistance: a potential role for protein kinase C-δ , 2002 .
[53] K. Petersen,et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. , 2002, The Journal of clinical investigation.
[54] L. Kuller,et al. Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. , 2003, American journal of physiology. Endocrinology and metabolism.
[55] I. Wanless,et al. Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors , 1990, Hepatology.
[56] M. Roden,et al. The Role of Lipid Accumulation in Liver and Muscle for Insulin Resistance and Type 2 Diabetes Mellitus in Humans , 2004, Reviews in Endocrine and Metabolic Disorders.
[57] A. Sanyal,et al. Clinical aspects of fatty liver disease. , 2004, Seminars in liver disease.
[58] J. Mckenney,et al. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.
[59] Roy Taylor,et al. Effects of an Engineered Human Anti–TNF-α Antibody (CDP571) on Insulin Sensitivity and Glycemic Control in Patients With NIDDM , 1996, Diabetes.
[60] A. Häkkinen,et al. Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy , 2002, AIDS.
[61] M. Lazar,et al. How Obesity Causes Diabetes: Not a Tall Tale , 2005, Science.
[62] J. Jessurun,et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. , 2005, The Journal of clinical investigation.
[63] M. Jensen,et al. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. , 2004, Journal of hepatology.
[64] E. Ferrannini,et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms , 2005, Diabetologia.
[65] L. Wilkins. New Investigator Awards , 2005 .
[66] M. Stumvoll,et al. Pathogenesis of Type 2 Diabetes , 2007, Endocrine research.
[67] A. Scheen,et al. No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients. , 2000, The Journal of clinical endocrinology and metabolism.
[68] J. McGarry. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. , 2002, Diabetes.
[69] T. Kadowaki,et al. Adiponectin and adiponectin receptors. , 2005, Endocrine reviews.
[70] Fredrik Karpe,et al. Selective partitioning of dietary fatty acids into the VLDL TG pool in the early postprandial period Published, JLR Papers in Press, August 16, 2003. DOI 10.1194/jlr.M300167-JLR200 , 2003, Journal of Lipid Research.
[71] D. Cook,et al. Real-time assessment of postprandial fat storage in liver and skeletal muscle in health and type 2 diabetes. , 2005, American journal of physiology. Endocrinology and metabolism.
[72] A. Häkkinen,et al. Liver-fat accumulation and insulin resistance in obese women with previous gestational diabetes. , 2002, Obesity research.
[73] L. J. Hardies,et al. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients , 2004, International Journal of Obesity.
[74] P. Arner. Resistin: yet another adipokine tells us that men are not mice , 2005, Diabetologia.
[75] Y. Iwamoto,et al. Prevalence of non‐alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults , 2005, Diabetic medicine : a journal of the British Diabetic Association.